Ihle et al., in their study, noticed that patients with refractory NSCLC that have G12C and G12V mutant variants had poor PFS (median survival = 1.84 months, p = 0.046) compared to the mutant variants G12A and G12D (median survival = 3.35 months) and patients with WT KRAS (median survival = 1.95 months) [68]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.